Efficacy and safety of Diphereline and Microreline 3.75mg in breast cancer patients
Phase 3
Recruiting
- Conditions
- Breast Cancer.Malignant neoplasm of breast
- Registration Number
- IRCT20201227049847N1
- Lead Sponsor
- Homa Pharmed Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 210
Inclusion Criteria
Age over 18 years
Positive estrogen and progesterone receptor
Premenopausal patients
Perimenopausal patients, if they have the same estradiol levels as premenopausal women.
Exclusion Criteria
Existence of metastasis
History of hysterectomy and oophorectomy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in Estradiol level over one year. Timepoint: Before the intervention, 3, 6 and 12 months after the intervention. Method of measurement: Blood test.
- Secondary Outcome Measures
Name Time Method Menopausal symptoms. Timepoint: Before the intervention, three, six, nine and twelve months after the intervention. Method of measurement: Menopause Rating Scale.;Drug side effects. Timepoint: Before the intervention, three, six, nine and twelve months after the intervention. Method of measurement: Drug side effects checklist.